Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Wellcome Trust and the Royal Society (211179/Z/18/Z)
CRUK Lung Cancer Centre of Excellence
Rosetrees Trust
University College London Hospitals Biomedical Research Centre
Radiation Research Unit at the Cancer Research UK City of London Centre (C7893/A28990)
Medical Research Council (MR/N013867/1)
- License Information
-
More Information
Article History
Received: 10 June 2022
Accepted: 9 November 2022
First Online: 7 December 2022
Declarations
:
: Not applicable
: Not applicable
: N.M. has received consultancy fees and has stock options in Achilles Therapeutics. N.M. holds European patents relating to targeting neoantigens (PCT/EP2016/ 059401), identifying patient response to immune checkpoint blockade (PCT/ EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221). The remaining authors declare that they have no competing interests.
